How BPC 157 works
BPC 157 is a stable pentadecapeptide fragment of human gastric juice protein. It upregulates VEGF and the FAK-paxillin pathway, pulling new capillaries and fibroblasts into damaged tissue while modulating nitric-oxide signalling. Repair speeds up because blood supply and cell migration arrive together.
Reported benefits
- Faster tendon, ligament and muscle healing
- Gut lining protection and repair
- Reduced local inflammation
- Improved capillary formation in damaged tissue
Reported side effects
Effects reported in published trials, case reports or post-market surveillance. Individual response varies; this list is educational and not exhaustive.
- Injection-site irritation
- Head-rush or light-headedness
- Nausea reported anecdotally
- No completed human safety trials
Serious or rare signals
- Prohibited in sport by WADA (S0 non-approved substances)
- Angiogenic activity raises theoretical concern with active cancer
Regulatory status & sources
Not FDA approved; the FDA placed BPC-157 in Category 2 for compounding in 2023, citing insufficient safety data.
Safety note
BPC 157 is presented here for research and educational purposes only. It is not offered for human consumption and nothing on this page is medical advice or a dosing protocol. Read the full safety and disclaimer page.